PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Global Vision, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Persistent Systems Showcases Pharma Solution Featuring Global Vision - Paxpro Compliance-based Design to Print Automation Solution Now Integrated with Global Vision’s Automated Proofreading Technologies (BSE & NSE: PERSISTENT) - PersistentSys.com / GlobalVisionInc.com
Persistent Systems Showcases Pharma Solution Featuring Global Vision

 

NewswireToday - /newswire/ - Montréal, Québec, Canada, 2013/02/26 - Paxpro Compliance-based Design to Print Automation Solution Now Integrated with Global Vision’s Automated Proofreading Technologies (BSE & NSE: PERSISTENT) - PersistentSys.com / GlobalVisionInc.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Persistent Systems (BSE & NSE: PERSISTENT), the global leader in software product and technology services today announced that the company will showcase its market leading Paxpro Design to Print (D2P) Automation Solutions for regulated industries, integrated with Global Vision’s suite of automated proofreading solutions. The integrated offering is being showcased at the Pharma Packaging and Labeling USA 2013 conference being held February 26 and 27 at the Hilton Philadelphia City Avenue Hotel.

“We are delighted to offer the pharmaceutical marketplace this tightly integrated joint solution as it provides packaging and QA specialists with exceptional control of their inspection and approval processes around labeling and artwork management,” said Ram Pazhayannur, VP Paxpro, a Persistent Systems Business Unit. “Global Vision’s complementary suite of solutions, validated for the pharmaceutical industry, was the clear choice for us, considering their leadership position in the inspection solution space.”

“We are excited to be working together with a D2P and PLM industry leader like Paxpro,” said Reuben Malz, President of Global Vision. “Pharmaceutical packaging and labeling is a complex process with multiple languages and SKUs that brand owners need to manage. By adding integrated proofreading solutions within the packaging workflow, the risk to the brand is greatly reduced.”

Persistent Systems will host technical demonstrations of its PaxPharma solution integrated with Global Vision’s inspection tools for text, artwork and print at the conference. PaxPharma and Global Vision’s Docu-Proof™, Digital-Page™ and ScanTVST™ solutions are both available immediately for purchase.

About Persistent Systems
Established in 1990, Persistent Systems (BSE & NSE: PERSISTENT) is a global company specializing in software product and technology services. For more than two decades, Persistent has been an innovation partner for the world’s largest technology brands, leading enterprises and pioneering start-ups. With a global team of more than 6,000 employees, Persistent has 300 customers spread across North America, Europe, and Asia. Today, Persistent focuses on developing best-in-class solutions in four key next-generation technology areas: Cloud Computing, Mobility, Analytics and Collaboration, for telecommunications, life sciences, consumer packaged goods, banking & financial services and healthcare verticals.

Paxpro, by Persistent Systems (persistentsys.com), is an Enterprise Collaboration Solution that helps integrate the Design to Print (D2P) supply-chain process, across pharmaceutical, food and beverage, health and beauty, telecom and other regulated industries. Paxpro solutions provide the backbone for brand managers to get their products released to market faster, error free and at costs significantly lower than with traditional ERP and PLM systems. Global brands across the world rely on Paxpro for their D2P processes, which are delivered securely over the cloud and in compliance with standards including 21 CFR Part 11 and GMP.

About Global Vision
Global Vision (globalvisioninc.com) is the world leader in the design and delivery of automated proofreading solutions. Its complete suite of advanced solutions featuring text-based, pixel-based and Braille inspection technologies are designed to eliminate printed artwork, text verification, and text comparison related errors, providing end-to-end security at every stage of the workflow process.

Global Vision solutions are widely interoperable and have received commercial endorsement from the world’s leading Pharmaceutical, Consumer Packaged Goods (CPG), and Artwork Management companies.

Headquartered in Montreal, Canada, Global Vision has worldwide representation.
All trademarks, trade names, service marks, and logos referenced herein belong to their respective companies.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Global Vision, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Persistent Systems Showcases Pharma Solution Featuring Global Vision

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Press Office - GlobalVisionInc.com 
514-624-4422 mspooner[.]globalvisioninc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Global Vision, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Global Vision, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)